FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:307-308 January 15, 2004 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Petitti, D. B. PubMed Citation

To the Editor: Petitti (Oct. 9 issue)¹ offers recommendations regarding the use of estrogen–progestin oral contraceptives. Since third-generation compounds containing desogestrel or gestodene as progestin are associated with a higher risk of venous thromboembolism than those containing other types of progestin,² it is preferable for women with an increased base-line risk of venous thromboembolism to use second-generation compounds. Among them are carriers of the factor V Leiden mutation, which is the most common cause of thrombophilia and is present at a frequency of 2 to 15 percent in populations of Caucasian descent.³ Petitti's statement that oral contraceptives are contraindicated in . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.